studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), atezolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06] IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99] IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88] IMpower-130 (all population), 2019 0.80 [0.65; 0.99] IMpower-130 (WT), 2019 0.79 [0.64; 0.98] IMpower-131 (ACnP), 2020 0.88 [0.73; 1.06] IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92] IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02] 0.80[0.74; 0.86]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 201890%5,470moderateserious deaths (OS) (extension)detailed resultsIMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08] 0.76[0.53; 1.08]IMpower-110 (TC3 or IC3), 202010%205NAnot evaluable PFS (extension)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86] IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82] IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81] 0.67[0.59; 0.77]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 202030%1,087moderatenot evaluable progression or deaths (PFS)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94] IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87] IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88] IMpower-130 (all population), 2019 0.65 [0.54; 0.78] IMpower-130 (WT), 2019 0.64 [0.54; 0.76] IMpower-131 (ACnP), 2020 0.71 [0.60; 0.85] IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68] IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72] IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06] 0.67[0.61; 0.75]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 20181061%5,750moderatelow DORdetailed resultsIMpower-130 (WT), 2019 2.41 [1.27; 4.60] IMpower-131 (ACnP), 2020 2.14 [1.13; 4.04] 2.27[1.44; 3.57]IMpower-130 (WT), 2019, IMpower-131 (ACnP), 202020%601moderatenot evaluable objective responses (ORR)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27] IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50] IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79] IMpower-130 (WT), 2019 2.07 [1.48; 2.89] IMpower-131 (ACnP), 2020 1.42 [1.05; 1.92] IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19] IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58] IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35] 1.45[1.15; 1.82]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018973%5,001moderatenot evaluable objective responses (ORR) (extension)detailed resultsIMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01] 1.68[0.94; 3.01]IMpower-110 (TC3 or IC3), 202010%205NAnot evaluable AE (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01] IMpower-130 (all population), 2019 2.05 [0.29; 14.63] IMpower-131 (ACnP), 2020 5.12 [1.11; 23.56] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65] 1.07[0.37; 3.10]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018466%2,709moderatenot evaluable AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55] IMpower-130 (all population), 2019 1.72 [1.19; 2.47] IMpower-131 (ACnP), 2020 1.37 [0.98; 1.90] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52] 1.01[0.55; 1.86]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018493%2,709moderatenot evaluable AE leading to death (grade 5)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15] IMpower-130 (all population), 2019 0.94 [0.47; 1.87] IMpower-131 (ACnP), 2020 2.59 [1.36; 4.92] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03] 1.28[0.78; 2.11]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018452%2,709moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61] IMpower-130 (all population), 2019 1.27 [0.88; 1.85] IMpower-131 (ACnP), 2020 2.09 [1.45; 3.02] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99] 1.12[0.62; 2.02]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018489%2,709moderatenot evaluable SAE (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44] IMpower-130 (all population), 2019 1.69 [1.22; 2.32] IMpower-131 (ACnP), 2020 2.28 [1.66; 3.14] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87] 1.53[1.11; 2.11]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018475%2,709moderatenot evaluable STRAE (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85] IMpower-130 (all population), 2019 2.09 [1.35; 3.24] IMpower-131 (ACnP), 2020 2.27 [1.46; 3.51] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00] 1.38[0.77; 2.47]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018486%2,709moderatenot evaluable TRAE (any grade)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40] IMpower-130 (all population), 2019 2.00 [1.01; 3.95] IMpower-131 (ACnP), 2020 1.80 [0.98; 3.28] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53] 0.92[0.33; 2.60]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018492%2,709moderatenot evaluable TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29] IMpower-130 (all population), 2019 1.79 [1.28; 2.50] IMpower-131 (ACnP), 2020 1.57 [1.14; 2.15] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83] 0.93[0.39; 2.23]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018496%2,709moderatenot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73] IMpower-130 (all population), 2019 3.97 [0.49; 31.97] IMpower-131 (ACnP), 2020 1.34 [0.30; 6.02] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01] 1.37[0.68; 2.78]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201840%2,709moderatenot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09] 1.32[0.15; 11.35]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 0.79[0.08; 7.60]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.62 [1.11; 2.36] IMpower-131 (ACnP), 2020 1.09 [0.76; 1.58] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89] 1.27[0.96; 1.68]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018325%2,160moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37] 0.78[0.19; 3.17]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Asthenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.48 [0.40; 5.52] IMpower-131 (ACnP), 2020 0.77 [0.28; 2.10] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30] 0.74[0.39; 1.40]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] IMpower-131 (ACnP), 2020 8.08 [0.43; 153.53] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10] 3.39[0.92; 12.50]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,004moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] IMpower-131 (ACnP), 2020 0.50 [0.02; 14.93] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 0.77[0.10; 5.99]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.86 [0.25; 2.95] IMpower-131 (ACnP), 2020 3.41 [0.93; 12.49] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 1.96[0.71; 5.43]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018329%2,160moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 6.05 [0.30; 121.16] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65] 3.12[0.29; 33.74]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.03 [0.49; 2.14] IMpower-131 (ACnP), 2020 1.44 [0.54; 3.83] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63] 1.65[0.72; 3.78]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018349%2,160moderatenot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] 0.49[0.01; 24.77]IMpower-130 (all population), 201910%705NAnot evaluable Epistaxis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59] 8.09[0.43; 153.59]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.02 [0.53; 1.96] IMpower-131 (ACnP), 2020 1.89 [0.75; 4.80] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03] 1.27[0.81; 1.99]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.66 [1.10; 6.46] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57] 1.78[1.04; 3.05]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018218%1,455moderatenot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87] IMpower-131 (ACnP), 2020 1.00 [0.06; 16.05] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59] 5.48[1.30; 23.18]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201831%2,004moderatenot evaluable Hypertension TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78] 1.00[0.57; 1.78]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51] IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 1.62[0.21; 12.58]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,004moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51] IMpower-131 (ACnP), 2020 4.02 [0.18; 89.44] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.18[0.30; 15.78]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,004moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51] IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 0.96[0.06; 15.37]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 202020%1,217moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.46 [0.72; 2.93] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09] 1.53[0.83; 2.81]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Myalgia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26] 1.66[0.21; 12.91]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 1.49[0.11; 19.42]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Nausea TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.61 [0.52; 5.00] IMpower-131 (ACnP), 2020 3.55 [0.73; 17.23] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57] 2.00[1.06; 3.77]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 1.49[0.11; 19.42]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.22 [0.86; 1.72] IMpower-131 (ACnP), 2020 0.93 [0.65; 1.35] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94] 1.12[0.90; 1.39]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56] 2.93[0.30; 28.98]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97] 0.50[0.02; 14.97]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.01 [0.37; 11.06] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01] 1.37[0.62; 3.02]IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201820%1,455moderatenot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 4.04 [0.45; 36.31] 4.04[0.45; 36.31]IMpower-131 (ACnP), 202010%668NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] IMpower-131 (ACnP), 2020 1.68 [0.40; 7.07] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15] 2.31[0.84; 6.37]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,004moderatenot evaluable Rash TRAE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34] IMpower-131 (ACnP), 2020 2.01 [0.18; 22.23] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 10.14 [0.55; 186.27] 2.28[0.63; 8.28]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,004moderatenot evaluable Sepsis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02] 2.01[0.07; 60.02]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32] 4.04[0.45; 36.32]IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201810%787NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.52 [0.83; 2.79] IMpower-131 (ACnP), 2020 1.16 [0.68; 2.00] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89] 1.21[0.85; 1.71]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.48 [0.40; 5.52] IMpower-131 (ACnP), 2020 3.02 [0.31; 29.16] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.21 [0.37; 3.99] 1.48[0.65; 3.36]IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 201830%2,160moderatenot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.23 [0.24; 6.38] 1.23[0.24; 6.38]IMpower-130 (all population), 201910%705NAnot evaluable Agranulocytosis (AE grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.24 [0.01; 7.31] 0.24[0.01; 7.31]IMpower-130 (all population), 201910%705NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] 0.49[0.01; 24.77]IMpower-130 (all population), 201910%705NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20] IMpower-130 (all population), 2019 1.47 [1.03; 2.11] 0.35[0.02; 6.18]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019297%1,254moderatenot evaluable Arthralgia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 7.97 [0.46; 139.30] 7.97[0.46; 139.30]IMpower-130 (all population), 201910%705NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89] IMpower-130 (all population), 2019 1.59 [0.58; 4.39] 0.88[0.21; 3.64]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019255%1,254moderatenot evaluable Back pain AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 3.97 [0.49; 31.97] 3.97[0.49; 31.97]IMpower-130 (all population), 201910%705NAnot evaluable Blood creatinine increased AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Colitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 2.96 [0.15; 59.25] 2.96[0.15; 59.25]IMpower-130 (all population), 201910%705NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34] IMpower-130 (all population), 2019 4.95 [0.27; 90.93] 1.97[0.43; 9.07]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable Cough AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14] IMpower-130 (all population), 2019 2.96 [0.15; 59.25] 2.40[0.25; 22.76]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] IMpower-130 (all population), 2019 0.98 [0.33; 2.90] 1.13[0.41; 3.16]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable Diabetes mellitus AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09] IMpower-130 (all population), 2019 0.87 [0.44; 1.70] 0.82[0.42; 1.58]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable Dizziness AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.03; 7.86] 0.49[0.03; 7.86]IMpower-130 (all population), 201910%705NAnot evaluable Dry skin AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.24 [0.01; 7.31] 0.24[0.01; 7.31]IMpower-130 (all population), 201910%705NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.01; 24.77] 0.49[0.01; 24.77]IMpower-130 (all population), 201910%705NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36] IMpower-130 (all population), 2019 5.61 [1.31; 24.06] 5.20[1.39; 19.45]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable Epistaxis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.03; 7.86] 0.49[0.03; 7.86]IMpower-130 (all population), 201910%705NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51] IMpower-130 (all population), 2019 1.28 [0.68; 2.43] 0.76[0.19; 2.97]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019263%1,254moderatenot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.00; 0.86] IMpower-130 (all population), 2019 0.90 [0.33; 2.46] 0.29[0.02; 4.63]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019272%1,254moderatenot evaluable Gastritis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Headache AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.61 [0.10; 3.68] IMpower-130 (all population), 2019 1.48 [0.30; 7.38] 1.00[0.30; 3.31]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.49 [0.03; 7.86] 0.49[0.03; 7.86]IMpower-130 (all population), 201910%705NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17] IMpower-130 (all population), 2019 0.98 [0.24; 3.96] 1.71[0.40; 7.37]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019229%1,254moderatenot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17] IMpower-130 (all population), 2019 0.73 [0.20; 2.62] 1.49[0.26; 8.74]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019252%1,254moderatenot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.03; 2.05] IMpower-130 (all population), 2019 1.57 [0.66; 3.73] 0.79[0.13; 4.82]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019261%1,254moderatenot evaluable Myalgia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.18 [0.02; 1.56] IMpower-130 (all population), 2019 1.59 [0.58; 4.39] 0.67[0.08; 5.36]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019269%1,254moderatenot evaluable Neutropenia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.03 [0.01; 0.14] IMpower-130 (all population), 2019 1.24 [0.88; 1.75] 0.22[0.01; 7.51]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019296%1,254moderatenot evaluable Pancytopenia (AE grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08] IMpower-130 (all population), 2019 0.49 [0.07; 3.49] 0.48[0.10; 2.18]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable Paraesthesia AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 1.97 [0.09; 43.77] 1.97[0.09; 43.77]IMpower-130 (all population), 201910%705NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.73 [0.12; 4.42] 0.73[0.12; 4.42]IMpower-130 (all population), 201910%705NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.73 [0.12; 4.42] 0.73[0.12; 4.42]IMpower-130 (all population), 201910%705NAnot evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.24; 3.96] 0.98[0.24; 3.96]IMpower-130 (all population), 201910%705NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.71 [0.26; 1.93] IMpower-130 (all population), 2019 1.40 [0.67; 2.93] 1.09[0.57; 2.07]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019212%1,254moderatenot evaluable Pneumonitis AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.24 [0.01; 7.31] 0.24[0.01; 7.31]IMpower-130 (all population), 201910%705NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.98[0.03; 29.35]IMpower-130 (all population), 201910%705NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73] IMpower-130 (all population), 2019 0.98 [0.03; 29.35] 0.67[0.06; 7.42]IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 201920%1,254moderatenot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:23 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866